📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
RPG Life Sciences Q3 FY26: Revenue Up 4.2% to ₹180 Cr, PAT Declines 20% YoY
RPG Life Sciences reported a modest 4.2% YoY revenue growth in Q3 FY26, reaching ₹180 crore, primarily driven by a 12.5% growth in its Domestic Formulations segment. However, profitability faced significant pressure as PAT declined 20% YoY to ₹27.9 crore and EBITDA margins contracted from 30.4% to 24.0%. The API segment was particularly weak, with a 19.4% revenue decline in 9M FY26 due to a fire incident at a manufacturing block. Despite these headwinds, the company remains debt-free and is proceeding with a ₹140 crore capex plan for global expansion.
Key Highlights
Q3 FY26 Revenue grew 4.2% YoY to ₹180 Cr, while 9M FY26 Revenue rose 4.0% to ₹530.6 Cr.
PAT for Q3 FY26 dropped 20% YoY to ₹27.9 Cr, with EBITDA margins contracting to 24.0% from 30.4%.
Domestic Formulations, contributing 70% of sales, grew 12.5% in 9M FY26, outperforming market growth.
API segment revenue fell 19.4% in 9M FY26, impacted by a fire incident in one of the manufacturing blocks.
The company maintains a debt-free balance sheet and is investing ₹140 Cr in capex to expand its international footprint.
💼 Action for Investors
The significant margin contraction and the fire-related disruption in the API segment are short-term negatives. Investors should watch for the recovery of API operations and the impact of the ₹140 crore capex on future growth before increasing exposure.
RPG Life Sciences Q3 FY26 Revenue Up 4.2% Y-o-Y to Rs 180 Cr; EBITDA Margin at 24%
RPG Life Sciences reported a steady performance for Q3 FY26 with revenue growing 4.2% Y-o-Y to Rs 180.0 crores. The company maintained a healthy EBITDA margin of 24.0%, reflecting operational efficiency despite a marginal Q-o-Q revenue dip from Rs 181.7 crores. Notably, the Domestic Formulations segment grew by 11.8% in the first nine months of FY26, significantly outperforming the Indian Pharmaceutical Market (IPM) growth of 8.2%. Overall 9M FY26 revenue reached Rs 530.6 crores, up from Rs 510.3 crores in the previous year.
Key Highlights
Q3 FY26 Revenue grew 4.2% Y-o-Y to Rs 180.0 crores vs Rs 172.7 crores in Q3 FY25
EBITDA margin remained robust at 24.0% for the quarter
Domestic Formulations business grew 11.8% in 9M FY26, outperforming the IPM growth of 8.2%
9M FY26 total revenue reached Rs 530.6 crores, a 4.0% increase Y-o-Y
Q-o-Q revenue saw a slight decline from Rs 181.7 crores to Rs 180.0 crores
💼 Action for Investors
Investors should take note of the company's consistent ability to outperform the domestic pharma market growth and maintain high margins. The stock remains a solid mid-cap pharma play focused on branded formulations and operational efficiency.
RPG Life Sciences Approves Q3 FY26 Unaudited Financial Results
RPG Life Sciences Limited has officially approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting, held on January 27, 2026, concluded with the submission of these results along with the Statutory Auditor's Limited Review Report. While the specific profit and revenue figures were not detailed in the cover letter, the filing confirms compliance with SEBI Listing Obligations. Investors should now examine the full financial tables to evaluate the company's performance trajectory for the fiscal year.
Key Highlights
Board approved unaudited financial results for the quarter ended December 31, 2025
Consolidated and standalone results for the nine-month period were submitted to exchanges
The board meeting lasted three and a half hours, concluding at 6:30 p.m.
Statutory auditors have provided a Limited Review Report for the period
💼 Action for Investors
Investors should review the detailed profit and loss statements to assess margin trends and revenue growth compared to the previous year. Monitor the stock's price action in the coming sessions for the market's reaction to the specific earnings data.